Oxatomide effects in follicular conjunctivitis of presumed allergic cause. A double-blind evaluation.
This double-blind study suggests that oxatomide may be considered a first-line alternative in the treatment of allergic follicular conjunctivitis. For 4 weeks 18 patients were treated with oxatomide at a dosage of 30 mg b.i.d. A randomized control group of 17 patients received a placebo. Already after 2 weeks, and more marked after 4 weeks, oxatomide produced a significantly higher reduction of itching and follicles than the placebo, involving a lower use of supplementary antihistamine medication. Globally, an excellent or good result was obtained in 78% of the oxatomide-treated patients but only in 29% of the placebo-treated patients. In the drug group 1 patient had gastrointestinal complaints and 1 felt slightly sleepy.
D000293:Adolescent; D000328:Adult; D002936:Cinnarizine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000150:complications; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D011537:Pruritus / Q000188:drug therapy; D011897:Random Allocation
D010879:Piperazines; D010919:Placebos; D002936:Cinnarizine; C015408:oxatomide